Get the Stockscreener App
20.20
3.30%
-0.69
Vtv Therapeutics Inc stock is traded at $20.20, with a volume of 6,850.
It is down -3.30% in the last 24 hours and up +44.65% over the past month.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
See More
Previous Close:
$20.89
Open:
$20.69
24h Volume:
6,850
Relative Volume:
0.35
Market Cap:
$52.77M
Revenue:
$5.02M
Net Income/Loss:
$-18.31M
P/E Ratio:
-4.4592
EPS:
-4.53
Net Cash Flow:
$-23.40M
1W Performance:
-6.93%
1M Performance:
+44.65%
6M Performance:
+22.80%
1Y Performance:
+133.26%
1-Day Range:
$20.20
$20.73
1-Week Range:
$19.02
$21.80
52-Week Range:
$8.10
$30.99
Vtv Therapeutics Inc Stock (VTVT) Company Profile
Name
Vtv Therapeutics Inc
Sector
Industry
Phone
336-841-0300
Address
3980 PREMIER DR, HIGH POINT, NC
Compare VTVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
20.20 | 52.77M | 5.02M | -18.31M | -23.40M | -4.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-30-19 | Initiated | H.C. Wainwright | Buy |
| Apr-10-18 | Downgrade | Stifel | Buy → Hold |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-08-18 | Initiated | Northland Capital | Outperform |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Sep-04-15 | Initiated | Canaccord Genuity | Buy |
| Aug-24-15 | Initiated | Piper Jaffray | Overweight |
| Aug-24-15 | Initiated | Stifel | Buy |
View All
Vtv Therapeutics Inc Stock (VTVT) Latest News
(VTVT) Investment Analysis - Stock Traders Daily
vTv Therapeutics (NASDAQ:VTVT) Earns Sell Rating from Analysts at StockNews.com - Defense World
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Trading (VTVT) With Integrated Risk Controls - Stock Traders Daily
vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com - MarketBeat
StockNews.com Begins Coverage on vTv Therapeutics (NASDAQ:VTVT) - Defense World
We're Keeping An Eye On vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Rate - Yahoo Finance
When the Price of (VTVT) Talks, People Listen - Stock Traders Daily
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
vTv Therapeutics Highlights Progress on Diabetes Treatment - TipRanks
Trend Tracker for (VTVT) - Stock Traders Daily
Where are the Opportunities in (VTVT) - Stock Traders Daily
Fmr LLC Takes $2.40 Million Position in vTv Therapeutics Inc. (NASDAQ:VTVT) - Defense World
vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Update - Defense World
Vimeo, Inc. (NASDAQ:VMEO) Sees Significant Increase in Short Interest - Defense World
vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated by Analysts at Alliance Global Partners - Defense World
Alliance Global Partners Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation - MSN
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER - The Malaysian Reserve
(VTVT) Long Term Investment Analysis - Stock Traders Daily
vTv Therapeutics (FRA:5VT0) EBITDA : €-20.38 Mil (TTM As of Sep. 2024) - GuruFocus.com
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference - The Manila Times
vTv Therapeutics to Present at Evercore HealthCONx Conference in December 2024 - StockTitan
vTv Therapeutics (STU:5VT0) Shares Outstanding (EOP) : 2.61 Mil (As of Sep. 2024) - GuruFocus.com
vTv Therapeutics (STU:5VT0) Operating Cash Flow per Share : €-4.95 (TTM As of Sep. 2024) - GuruFocus.com
vTv Therapeutics (STU:5VT0) Net Issuance of Preferred Stock : €0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
vTv Therapeutics (STU:5VT0) Change In Receivables : €-0.12 Mil (TTM As of Sep. 2024) - GuruFocus.com
vTv Therapeutics (STU:5VT0) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
vTv Therapeutics (STU:5VT0) Cash Flow from Financing : €48.09 Mil (TTM As of Sep. 2024) - GuruFocus.com
VTv Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors - GlobeNewswire
Insider Buying: Paul Sekhri Acquires Shares of vTv Therapeutics Inc (VTVT) - GuruFocus.com
vTv therapeutics CEO Paul Sekhri buys $83,811 in stock - Investing.com
vTv Therapeutics (NASDAQ:VTVT) shareholders are up 29% this past week, but still in the red over the last five years - Simply Wall St
vTv Therapeutics (NASDAQ:VTVT) adds US$9.5m to market cap in the past 7 days, though investors from five years ago are still down 71% - Yahoo Finance
Objective long/short (VTVT) Report - Stock Traders Daily
vTv Therapeutics (FRA:5VT0) 5-Year EBITDA Growth Rate : 25.50% (As of Jun. 2024) - GuruFocus.com
VTv Therapeutics: Q3 Earnings Snapshot - Darien Times
NeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance - The Manila Times
vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update - GlobeNewswire
Vtv Therapeutics Inc Stock (VTVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vtv Therapeutics Inc Stock (VTVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SEKHRI PAUL J | Pres, CEO and Exec Chairperson |
Nov 18 '24 |
Buy |
16.96 |
1,844 |
31,269 |
5,000 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):